Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company anticipates that Bcl-3 will progress to clinical trials in 2016.
London, GB
Size (employees)
5 (est)+25%
Tiziana Life Sciences was founded in 2013 and is headquartered in London, GB

Tiziana Life Sciences Office Locations

Tiziana Life Sciences has an office in London
London, GB (HQ)
18 South St

Tiziana Life Sciences Data and Metrics

Tiziana Life Sciences Financial Metrics

Tiziana Life Sciences's revenue was reported to be (£6.3 m) in FY, 2015 which is a 692% increase from the previous period.

Net income (FY, 2016)

(7.2 m)

Market capitalization (25-Jul-2017)

153.9 m

Closing share price (25-Jul-2017)


Cash (31-Dec-2016)

4.7 m
Tiziana Life Sciences's current market capitalization is £153.9 m.
GBPFY, 2014FY, 2015FY, 2016


(794 k)(6.3 m)

Revenue growth, %


Pre tax profit

(3.4 m)(8.6 m)(7.3 m)

Net Income

(3.3 m)(8.6 m)(7.2 m)
GBPFY, 2014FY, 2015FY, 2016


2.3 m8.9 m4.7 m

Current Assets

2.5 m9.3 m5 m


28 k

Total Assets

2.5 m9.3 m5.1 m

Accounts Payable

41 k314 k1.2 m

Current Liabilities

683 k746 k1.7 m

Total Liabilities

683 k746 k1.7 m

Retained Earnings

(3.3 m)(8.6 m)(7.2 m)

Total Equity

1.8 m8.5 m3.3 m

Financial Leverage

1.4 x1.1 x1.5 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(2.2 m)(5.5 m)(5.1 m)

Cash From Financing Activities

4.4 m12.1 m1.2 m

Income Taxes Paid

60 k89 k
Y, 2016

Financial Leverage

1.5 x

Tiziana Life Sciences Market Value History

Traffic Overview of Tiziana Life Sciences

Tiziana Life Sciences Online and Social Media Presence

Tiziana Life Sciences News and Updates

Thousands of Sardinian DNA samples go missing from research laboratory

Italian prosecutors investigate alleged theft of 14,000 test tubes that could hold the secret to why residents live such long livesItalian prosecutors have opened an investigation into the alleged theft of thousands of DNA samples from a research laboratory in Sardinia that had been collected more t…

Ethical questions raised in search for Sardinian centenarians' secrets

Samples from residents of Sardinia’s ‘Blue Zone’ famed for longevity have been sold to for-profit research firm TizianaThere is something like gold flowing through the veins of 100-year-old Maria Tegas, and everyone wants a piece of the treasure.The centenarian, who lives in a poor and remote area o…

UK firm buys Sardinian DNA samples for research into disease and ageing

Tiziana Life Sciences says prevalence of centenarians in Ogliastra region of Italian island is almost 50 times that of UK or USA British biotech company hopes a genetic study of a unique population of centenarians in eastern Sardinia could help to develop new drugs and therapies.Tiziana Life Science…

Tiziana Life Sciences Company Life and Culture

You may also be interested in